ArticleTranslational andrology and urology2026
Feasibility and early outcomes of salvage robot-assisted radical prostatectomy after focal therapy failure for localized prostate cancer.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Focal therapy (FT) provides an intermediate treatment option between active surveillance and radical therapy for localized prostate cancer. While local recurrence remains an important clinical concern, and post-treatment anatomical changes may complicate the detection and localization of recurrent lesions. This study aimed to evaluate the feasibility and early outcomes of salvage robot-assisted radical prostatectomy (S-RARP) after FT failure and to explore the potential incremental value of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) over multiparametric magnetic resonance imaging (mpMRI) for recurrence localization. Methods: A retrospective analysis was conducted on eight patients who underwent S-RARP following recurrence after primary FT. Patient demographics, imaging data (mpMRI and PSMA PET/CT), and surgical outcomes were analyzed. Pathological specimens were examined using whole-mount sections. Results: This study of 8 patients undergoing S-RARP after FT recurrence found that, despite pathological upgrading and out-of-field recurrence being common at recurrence, the salvage procedure was technically feasible, and was associated with promising early outcomes, including negative surgical margins in all cases, no biochemical recurrence during a median follow-up of 21 months, and recovery of urinary continence. PSMA PET/CT could identify suspicious recurrent lesions that are negative on mpMRI. Conclusions: S-RARP appeared to be a technically feasible salvage treatment with promising early oncological and functional outcomes, due to the high incidence of pathological upgrading and multifocal recurrence of FT. PSMA PET/CT may complement mpMRI in post-FT surveillance and may help identify recurrence when mpMRI findings are equivocal or negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.